The role of claudin-4 in the development of gastric cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Shah MA. Update on metastatic gastric and esophageal cancers. J Clin Oncol. 2015;33(16):1760–1769.
   PubMed Web of Science ®Google Scholar
• Lal-Nag M, Morin PJ. The claudins. Genome Biol. 2009;10(8):235.
   PubMed Web of Science ®Google Scholar
• Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer. 2006;6:186.
   PubMed Web of Science ®Google Scholar
• Jung H, Jun KH, Jung JH, et al. The expression of claudin-1, claudin-2, claudin-3, and claudin-4 in gastric cancer tissue. J Surg Res. 2011;167(2):e185–e191.
   PubMed Web of Science ®Google Scholar
• Chang TL, Ito K, Ko TK, et al. Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells. Gastroenterology. 2010;138(1):255–265.
   PubMed Web of Science ®Google Scholar
• Song X, Chen HX, Wang XY, et al. H. pylori-encoded CagA disrupts tight junctions and induces invasiveness of AGS gastric carcinoma cells via Cdx2-dependent targeting of Claudin-2. Cell Immunol. 2013;286(1–2):22–30.
   PubMed Web of Science ®Google Scholar
• Okugawa T, Oshima T, Chen X, et al. Down-regulation of claudin-3 is associated with proliferative potential in early gastric cancers. Dig Dis Sci. 2012;57(6):1562–1567.
   PubMed Web of Science ®Google Scholar
• Moris D, Schizas D, Michalinos A, et al. The expression of Claudin-4 in gastric cancer tissue: A single center experience. J Buon. 2017;22(2):403–409.
   PubMed Web of Science ®Google Scholar
• Soini Y, Tommola S, Helin H, et al. Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. Virchows Arch. 2006;448(1):52–58.
   PubMed Web of Science ®Google Scholar
• Gao F, Li M, Xiang R, et al. Expression of CLDN6 in tissues of gastric cancer patients: association with clinical pathology and prognosis. Oncol Lett. 2019;17:4621–4625.
   PubMed Web of Science ®Google Scholar
• Coati I, Lotz G, Fanelli GN, et al. Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. Br J Cancer. 2019;121(3):257–263.
   PubMed Web of Science ®Google Scholar
• Gress TM, Muller-Pillasch F, Geng M, et al. A pancreatic cancer-specific expression profile. Oncogene. 1996;13(8):1819–1830.
   PubMed Web of Science ®Google Scholar
• Wang H, Yang X. The expression patterns of tight junction protein claudin-1, -3, and -4 in human gastric neoplasms and adjacent non-neoplastic tissues. Int J Clin Exp Pathol. 2015;8(1):881–887.
   PubMed Web of Science ®Google Scholar
• Seckin Y, Arici S, Harputluoglu M, et al. Expression of claudin-4 and beta-catenin in gastric premalignant lesions. Acta Gastroenterol Belg. 2009;72:407–412.
   PubMed Web of Science ®Google Scholar
• Cunningham SC, Kamangar F, Kim MP, et al. Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions. Cancer Epidemiol Biomarkers Prev. 2006;15(2):281–287.
   PubMed Web of Science ®Google Scholar
• Guanizo AC, Fernando CD, Garama DJ, et al. STAT3: a multifaceted oncoprotein. Growth Factors. 2018;36(1–2):1–14.
   PubMed Web of Science ®Google Scholar
• Gunther C, Neumann H, Neurath MF, et al. Apoptosis, necrosis and necroptosis: cell death regulation in the intestinal epithelium. Gut. 2013;62(7):1062–1071.
   PubMed Web of Science ®Google Scholar
• Yakata Y, Nakayama T, Yoshizaki A, et al. Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis. Int J Oncol. 2007;30:437–442.
   PubMed Web of Science ®Google Scholar
• Garcia-Hernandez V, Flores-Maldonado C, Rincon-Heredia R, et al. EGF regulates claudin-2 and -4 expression through Src and STAT3 in MDCK cells. J Cell Physiol. 2015;230(1):105–115.
   PubMed Web of Science ®Google Scholar
• Polk DB, Peek RJ. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010;10(6):403–414.
   PubMed Web of Science ®Google Scholar
• Fedwick JP, Lapointe TK, Meddings JB, et al. Helicobacter pylori activates myosin light-chain kinase to disrupt claudin-4 and claudin-5 and increase epithelial permeability. Infect Immun. 2005;73(12):7844–7852.
   PubMed Web of Science ®Google Scholar
• Chavarria-Velazquez CO, Torres-Martinez AC, Montano LF, et al. TLR2 activation induced by H. pylori LPS promotes the differential expression of claudin-4, -6, -7 and -9 via either STAT3 and ERK1/2 in AGS cells. Immunobiology. 2018;223:38–48.
   PubMed Web of Science ®Google Scholar
• Kang GH, Shim YH, Jung HY, et al. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res. 2001;61:2847–2851.
   PubMed Web of Science ®Google Scholar
• Qu Y, Dang S, Hou P. Gene methylation in gastric cancer. Clin Chim Acta. 2013;424:53–65.
   PubMed Web of Science ®Google Scholar
• Choi J, Kim SG, Kim BG, et al. Helicobacter pylori eradication modulates aberrant CpG island hypermethylation in gastric carcinogenesis. Korean J Gastroenterol. 2016;68(5):253–259.
   PubMedGoogle Scholar
• Kwon MJ, Kim SH, Jeong HM, et al. Claudin-4 overexpression is associated with epigenetic derepression in gastric carcinoma. Lab Invest. 2011;91(11):1652–1667.
   PubMed Web of Science ®Google Scholar
• Sato F, Meltzer SJ. CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer-Am Cancer Soc. 2006;106(3):483–493.
   PubMed Web of Science ®Google Scholar
• Xie Y, Liu L. Analysis of correlation between HP infection and activation of PI3K/Akt pathway in mucosal tissues of gastric cancer and precancerous lesions. Oncol Lett. 2018;16:5615–5620.
   PubMed Web of Science ®Google Scholar
• Luo J, Wang H, Chen H, et al. CLDN4 silencing promotes proliferation and reduces chemotherapy sensitivity of gastric cancer cells through activation of PI3K/Akt signaling pathway. Exp Physiol. 2020;105(6):979–988.
   PubMed Web of Science ®Google Scholar
• Kamata I, Ishikawa Y, Akishima-Fukasawa Y, et al. Significance of lymphatic invasion and cancer invasion-related proteins on lymph node metastasis in gastric cancer. J Gastroenterol Hepatol. 2009;24(9):1527–1533.
   PubMed Web of Science ®Google Scholar
• Lee LY, Wu CM, Wang CC, et al. Expression of matrix metalloproteinases MMP-2 and MMP-9 in gastric cancer and their relation to claudin-4 expression. Histol Histopathol. 2008;23(5):515–521.
   PubMed Web of Science ®Google Scholar
• Katoh M. Epithelial-mesenchymal transition in gastric cancer (Review). Int J Oncol. 2005;27(6):1677–1683.
   PubMed Web of Science ®Google Scholar
• Ikenouchi J, Matsuda M, Furuse M, et al. Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by Snail. J Cell Sci. 2003;116(Pt 10):1959–1967.
   PubMed Web of Science ®Google Scholar
• Cano A, Perez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000;2(2):76–83.
   PubMed Web of Science ®Google Scholar
• Song YX, Sun JX, Zhao JH, et al. Non-coding RNAs participate in the regulatory network of CLDN4 via ceRNA mediated miRNA evasion. Nat Commun. 2017;8(1):289.
   PubMed Web of Science ®Google Scholar
• Pecoraro A, Carotenuto P, Russo G, et al. Ribosomal protein uL3 targets E2F1 and Cyclin D1 in cancer cell response to nucleolar stress. Sci Rep. 2019;9(1):15431.
   PubMed Web of Science ®Google Scholar
• Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.
   PubMedGoogle Scholar
• Shareef MM, Radi DM, Eid AM. Tight junction protein claudin 4 in gastric carcinoma and its relation to lymphangiogenic activity. Arab J Gastroenterol. 2015;16(3-4):105–112.
   PubMed Web of Science ®Google Scholar
• Zhu JL, Gao P, Wang ZN, et al. Clinicopathological significance of claudin-4 in gastric carcinoma. World J Surg Onc. 2013;11(1):150.
   PubMed Web of Science ®Google Scholar
• Resnick MB, Gavilanez M, Newton E, et al. Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum Pathol. 2005;36(8):886–892.
   PubMed Web of Science ®Google Scholar
• Ohtani S, Terashima M, Satoh J, et al. Expression of tight-junction-associated proteins in human gastric cancer: downregulation of claudin-4 correlates with tumor aggressiveness and survival. Gastric Cancer. 2009;12(1):43–51.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhao J, Li A, et al. Clinicopathological significance of claudin 4 expression in gastric carcinoma: a systematic review and meta-analysis. Onco Targets Ther. 2016;9:3205–3212.
   PubMed Web of Science ®Google Scholar
• Lee SK, Moon J, Park SW, et al. Loss of the tight junction protein claudin 4 correlates with histological growth-pattern and differentiation in advanced gastric adenocarcinoma. Oncol Rep. 2005;13:193–199.
   PubMed Web of Science ®Google Scholar
• Kuo WL, Lee LY, Wu CM, et al. Differential expression of claudin-4 between intestinal and diffuse-type gastric cancer. Oncol Rep. 2006;16(4):729–734.
   PubMed Web of Science ®Google Scholar
• Yuasa Y. Control of gut differentiation and intestinal-type gastric carcinogenesis. Nat Rev Cancer. 2003;3(8):592–600.
   PubMed Web of Science ®Google Scholar
• Satake S, Semba S, Matsuda Y, et al. Cdx2 transcription factor regulates claudin-3 and claudin-4 expression during intestinal differentiation of gastric carcinoma. Pathol Int. 2008;58(3):156–163.
   PubMed Web of Science ®Google Scholar
• Fan Z, Li J, Dong B, et al. Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis. Clin Cancer Res. 2005;11(17):6162–6170.
   PubMed Web of Science ®Google Scholar
• Singh SS, Yap WN, Arfuso F, et al. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine? World J Gastroenterol. 2015;21(43):12261–12273.
   PubMed Web of Science ®Google Scholar
• Yan R, Li K, Yuan DW, et al. Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1. Int J Oncol. 2018;53(6):2566–2578.
   PubMed Web of Science ®Google Scholar
• Li L, Zhu X, Shou T, et al. MicroRNA-28 promotes cell proliferation and invasion in gastric cancer via the PTEN/PI3K/AKT signalling pathway. Mol Med Rep. 2018;17(3):4003–4010.
   PubMed Web of Science ®Google Scholar
• Cao B, Liu C, Yang G. Down-regulation of lncRNA ADAMTS9-AS2 contributes to gastric cancer development via activation of PI3K/Akt pathway. Biomed Pharmacother. 2018;107:185–193.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhang J, Hou L, et al. LncRNA AK023391 promotes tumorigenesis and invasion of gastric cancer through activation of the PI3K/Akt signaling pathway. J Exp Clin Cancer Res. 2017;36(1):194.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen P, Yin W, et al. Nectin-4 promotes gastric cancer progression via the PI3K/AKT signaling pathway. Hum Pathol. 2018;72:107–116.
   PubMed Web of Science ®Google Scholar
• Tang L, Long Z, Zhao N, et al. NES1/KLK10 promotes trastuzumab resistance via activation of PI3K/AKT signaling pathway in gastric cancer. J Cell Biochem. 2018;119(8):6398–6407.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Lin Z, He Y, et al. The long noncoding RNA D63785 regulates chemotherapy sensitivity in human gastric cancer by targeting miR-422a. Mol Ther Nucleic Acids. 2018;12:405–419.
   PubMedGoogle Scholar
• Li Q, Wang JX, He YQ, et al. MicroRNA-185 regulates chemotherapeutic sensitivity in gastric cancer by targeting apoptosis repressor with caspase recruitment domain. Cell Death Dis. 2014;5:e1197.
   PubMed Web of Science ®Google Scholar
• Zhao J, Du P, Cui P, et al. LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer. Oncogene. 2018;37(30):4094–4109.
   PubMed Web of Science ®Google Scholar
• Huang S, Chen M, Ding X, et al. Proton pump inhibitor selectively suppresses proliferation and restores the chemosensitivity of gastric cancer cells by inhibiting STAT3 signaling pathway. Int Immunopharmacol. 2013;17(3):585–592.
   PubMed Web of Science ®Google Scholar
• Koh JS, Joo MK, Park JJ, et al. Inhibition of STAT3 in gastric cancer: role of pantoprazole as SHP-1 inducer. Cell Biosci. 2018;8:50.
   PubMed Web of Science ®Google Scholar
• Freedman JC, Shrestha A, McClane BA. Clostridium perfringens enterotoxin: action, genetics, and translational applications. Toxins (Basel). 2016;8(3):73.
   PubMed Web of Science ®Google Scholar
• Liang ZY, Kang X, Chen H, et al. Effect of Clostridium perfringens enterotoxin on gastric cancer cells SGC7901 which highly expressed claudin-4 protein. World J Gastrointest Oncol. 2017;9(4):153–159.
   PubMed Web of Science ®Google Scholar
• Saeki R, Kondoh M, Kakutani H, et al. A novel tumor-targeted therapy using a claudin-4-targeting molecule. Mol Pharmacol. 2009;76(4):918–926.
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Kawahigashi Y, Hata T, et al. Efficacy and safety evaluation of claudin-4-targeted antitumor therapy using a human and mouse cross-reactive monoclonal antibody. Pharmacol Res Perspect. 2016;4(5):e266.
   Web of Science ®Google Scholar